Interestingly, SGLT2 inhibitors such as canagliflozin and empagliflozin have shown promising results in the field of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and epilepsy [15], as they possess the advantage of crossing the blood–brain barrier (BBB), after which they have shown ability to reduce oxidative stress and inflammatory processes, which validates their activation, absorbance, and exposure profiles in the brain [16,17,18,19,20,21,22,23,24,25,26,27,28,29]. This evidence concerns the gene SLC5A2 and nervous system disorder.